Burt's Bees announces that the Journal of Drugs in Dermatology published clinical data supporting the efficacy of Burt’s Bees nature-based sensitive skin regimen at maintaining healthy skin barrier function.
The company's nature-based regimen delivered improved skin health vs. a dermatologist-recommended synthetic regimen during a 4-week double-blind, randomized study.
"The data suggest that nature-based products can be effective for patients who seek alternatives to conventional, synthetic skin care products," says the study’s principal investigator.
Burt's Bees is subsidiary of Clorox (NYSE:CLX).
CLX -0.071% premarket to $140.11.
Source: Press Release
Subscribe for full text news in your inbox